左乙拉西坦治疗小儿热性惊厥的效果及对血清神经元特异性烯醇化酶、S-100β蛋白表达的影响  

Effect of Levetiracetam on children with febrile seizure and its effect on expression of neuron-specific enolase and S-100β protein in serum

作　　者：丁鸿飞 朱香兰 章笑安 王叶萍 陈鹏 董灵 卓超 DING Hongfei;ZHU Xianglan;ZHANG Xiao′an;WANG Yeping;CHEN Peng;DONG Ling;ZHUO Chao(Department of Pediatrics,Changxing People′s Hospital of Zhejiang Province(Changxing Hospital,the Second Affiliated Hospital of Zhejiang University Medical College),Zhejiang Province,Changxing 313100,China;Department of Clinical Laboratory,Changxing People′s Hospital of Zhejiang Province(Changxing Hospital,the Second Affiliated Hospital of Zhejiang University Medical College),Zhejiang Province,Changxing 313100,China;Deparement of Clinical Laboratory,the First Affiliated Hospital of Wannan Medical College of Anhui Province,Anhui Province,Wannan 241001,China)

机构地区：[1]浙江省长兴县人民医院(浙江大学医学院附属第二医院长兴院区)儿科,浙江长兴313100 [2]浙江省长兴县人民医院(浙江大学医学院附属第二医院长兴院区)检验科,浙江长兴313100 [3]安徽省皖南医学院第一附属医院戈矶山医院检验科,安徽皖南241001

出　　处：《中国医药导报》2019年第36期119-122,共4页China Medical Herald

基　　金：浙江省湖州市科技计划基金项目（2017GY56）

摘　　要：目的探究左乙拉西坦治疗小儿热性惊厥(FS)的效果及对血清神经元特异性烯醇化酶(NSE)、S-100β蛋白(S-100β)表达的影响。方法选取2017年11月~2019年4月浙江省长兴县人民医院儿科住院FS患儿70例作为研究对象,根据随机数字表法分为对照组和观察组,每组各35例。对照组口服地西泮片治疗,观察组口服左乙拉西坦片治疗。疗程为3 d,1个疗程治疗后,随访观察半年至1年。比较两组患儿惊厥复发率、不良反应发生率。检测患儿治疗前后NSE和S-100β水平。结果研究及随访过程中,对照组因主动退出研究、依从性差、随访释放等脱落5例,观察组脱落3例,为维持数量平衡性,最终各组均纳入30例。随访半年至1年,两组患儿惊厥复发率比较,差异无统计学意义(P>0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05);治疗前两组NSE、S-100β比较,差异无统计学意义(P>0.05);治疗后两组NSE、S-100β均较治疗前降低,且观察组NSE、S-100β均低于对照组,差异均有统计学意义(均P<0.05)。结论左乙拉西坦可有效预防FS反复发作,其复发预防疗效与地西泮相当。其临床应用安全性高,不良反应少,可有效改善FS患儿的脑神经因子NSE、S-100β水平,具有良好的脑保护作用。Objective To investigate the effect of Levetiracetam on children with febrile seizure(FS)and its effect on the expression of neuron-specific enolase(NSE)and S-100 Mongolian protein(S-100β)in serum.Methods From November 2017 to April 2019,70 children with FS in Department of Pediatrics,Changxing People′s Hospital of Zhe-jiang Province were selected as the study objects,According to the random number table method,the patients were di-vided into control group and observation group,35 cases in each group.The control group was treated with oral Di-azepam Tablets,while the observation group was treated with oral Levetiracetam Tablets.The course of treatment was set as 3 d.After one course of treatment,the patients were followed up for 6 months to 1 year.The recurrence rate of convulsion and incidence of adverse reactions were compared between the two groups.NSE and S-100 were measured before and after treatment.Results During the study and follow-up,5 patients in the control group dropped out due to active withdrawal,poor compliance and follow-up release,while 3 patients in the observation group dropped out.In or-der to maintain the quantity balance,30 patients were eventually included in each group.Follow-up for 6 months to 1 year showed no statistically significant dif-ference in the recurrence rate of convulsion between the two groups(P>0.05).The incidence of adverse reactions in the observation group was lower than that in the con-trol group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant differ-ence in NSE and S-100 between the two groups(P>0.05).NSE and S-100 in both groups were lower than those be-fore treatment,and NSE and S-100 in the observation group were lower than those in the control group,with statistical-ly significant differences(all P<0.05).Conclusion Levetiracetam can effectively prevent FS recurrence,and its re-lapse prevention effect is equivalent to that of Diazepam.With high clinical safety and less adverse reactions,it can ef-fectively improv

关 键 词：左乙拉西坦 地西泮 小儿热性惊厥 复发 安全性 神经元特异性烯醇化酶 S-100Β蛋白 

分 类 号：R742.1[医药卫生—神经病学与精神病学]